{{Rsnum
|rsid=17147528
|Chromosome=5
|position=121270010
|Orientation=plus
|GMAF=0.06198
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.0 | 4.4 | 95.6
| HCB | 0.0 | 0.0 | 100.0
| JPT | 0.0 | 0.0 | 100.0
| YRI | 4.1 | 33.3 | 62.6
| ASW | 0.0 | 28.1 | 71.9
| CHB | 0.0 | 0.0 | 100.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 5.9 | 94.1
| LWK | 4.5 | 38.2 | 57.3
| MEX | 0.0 | 8.6 | 91.4
| MKK | 5.8 | 30.1 | 64.1
| TSI | 0.0 | 3.9 | 96.1
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs17147528
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.05, combined P value= 1.96E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470207
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs17147528
|overall_frequency_n=12
|overall_frequency_d=126
|overall_frequency=0.0952381
|n_genomes=10
|n_genomes_annotated=0
|n_haplomes=11
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | HumanOmni1Quad}}